HomeAI · summaries
Storia in 7 fonti
FDA approves Regeneron’s drug for ultra-rare disease that turns tissue to bone
FDA approved Regeneron's Pasatru (garetosmab) for FOP, a rare disease affecting ~900 patients. Annual list price ranges $693K–$2.1M based on weight.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
FDA Approves Activin Signaling Inhibitor for Bone Disorder
Ultra-rare fibrodysplasia ossificans progressiva now has its second approved drug
- ·
statnews.com
Regeneron drug for disease that causes dangerous bone growth earns FDA approval
A Regeneron drug that treats an ultra-rare disease that causes bone to form where it's not meant to be has won approval.
